Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026

Phase 3remibrutinibPositive

AI Analysis

Summary

Novartis will present Phase III REMODEL-1/-2 results for remibrutinib in multiple sclerosis at MSToronto2026, featuring 46 abstracts from its MS portfolio highlighting the company's commitment to advancing MS treatment options.

Clinical Trial Data

Phase

Phase III

Outcome Details

Late-breaking Phase III REMODEL-1/-2 results presented at MSToronto2026

Importance:6/10

Sentiment:

0.60

multiple sclerosisPhase IIIlate-breaking dataconference presentationremibrutinib

Related Companies

$NVS

Read the original article

Published by GlobeNewswire Pharma on October 7, 2026 11:00 AM

Read Original